Diabetes/Metabolism Research and Reviews,
Journal Year:
2024,
Volume and Issue:
40(4)
Published: May 1, 2024
Abstract
Diabetic
kidney
disease
(DKD),
one
of
the
common
microvascular
complications
diabetes,
is
increasing
in
prevalence
worldwide
and
can
lead
to
End‐stage
renal
disease.
However,
there
are
still
gaps
our
understanding
pathophysiology
DKD,
both
current
clinical
diagnostic
methods
treatment
strategies
have
drawbacks.
According
recent
research,
long
non‐coding
RNAs
(lncRNAs)
intimately
linked
developmental
process
DKD
could
be
viable
targets
for
decisions
therapeutic
interventions.
Here,
we
review
insights
gained
into
lncRNAs
pathological
changes
such
as
mesangial
expansion,
podocyte
injury,
tubular
interstitial
fibrosis.
We
also
discuss
applications
DKD‐associated
biomarkers
targets,
well
their
limitations
challenges,
provide
new
prevention,
diagnosis,
DKD.
Antioxidants,
Journal Year:
2023,
Volume and Issue:
12(4), P. 898 - 898
Published: April 7, 2023
Metabolic
imbalances
and
persistent
hyperglycemia
are
widely
recognized
as
driving
forces
for
augmented
cytosolic
mitochondrial
reactive
oxygen
species
(ROS)
in
diabetes
mellitus
(DM),
fostering
the
development
of
vascular
complications
such
diabetic
nephropathy,
cardiomyopathy,
neuropathy,
retinopathy.
Therefore,
specific
therapeutic
approaches
capable
modulating
oxidative
milieu
may
provide
a
preventative
and/or
benefit
against
cardiovascular
patients.
Recent
studies
have
demonstrated
epigenetic
alterations
circulating
tissue-specific
long
non-coding
RNA
(lncRNA)
signatures
DM
regulating
function
under
stress.
Intriguingly,
over
past
decade
mitochondria-targeted
antioxidants
(MTAs)
emerged
promising
option
managing
stress-induced
diseases.
Here,
we
review
present
status
lncRNA
diagnostic
biomarker
potential
regulator
stress
DM.
We
also
discuss
recent
advances
using
MTAs
different
animal
models
clinical
trials.
summarize
prospects
challenges
use
treating
diseases
their
application
translation
medicine,
which
be
beneficial
MTA
drug
design
development,
translational
medicine.
Diabetes Metabolic Syndrome and Obesity,
Journal Year:
2025,
Volume and Issue:
Volume 18, P. 637 - 651
Published: Feb. 1, 2025
Diabetic
nephropathy
(DN)
could
impair
the
function
of
glomerular
filtration
barrier
by
damaging
podocytes.
Extant
research
has
demonstrated
that
aldosterone
plays
a
crucial
role
in
this
progression.
Finerenone
is
novel,
high-selective
mineralocorticoid
receptor
antagonist
been
to
be
efficacious
renal
protection
DN
patients,
albeit
with
an
unclear
underlying
mechanism.
Podocytes
were
stimulated
RPMI
1640
medium
containing
different
concentrations
glucose
and
treated
finerenone
evaluate
protective
effect
on
podocytes
high
environment.
Intraperitoneal
injection
STZ
was
used
induce
diabetic
rats
intragastric
administration
or
vehicles,
changes
function,
pathological
tissue
protein
expression
assayed.
Cell
experiment
showed
epithelial-mesenchymal
transition
(EMT).
After
treatment,
we
accessed
EMT-related
found
EMT
reversed.
Besides,
cell
migration
capacity
cytoskeleton
also
ameliorated.
To
further
explore
mechanism,
upregulate
Krüppel-like
factor
5
(KLF5)
which
downregulated
silence
KLF5
presence
finerenone,
rescue
counteracted
KLF5.
In
animal
experiment,
after
treatment
level
blood
creatinine
decreased
compared
group
while
urea
nitrogen
(BUN)
potassium
no
significant
difference.
The
alterations
got
normalize
protein,
nephrin,
kidney
rats.
Our
results
suggest
alleviate
glucose-induced
podocyte
via
regulating
Further
investigation
warranted
elucidate
precise